Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://ncbi.nlm.nih.gov/pubmed/31165048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars